Read More 1 minute read Analyst Ratings News Price Target Mizuho Maintains Buy on Alkermes, Lowers Price Target to $34 By Benzinga Newsdesk July 28, 8:11 AM Mizuho analyst Vamil Divan maintains Alkermes (NASDAQ:ALKS) with a Buy and lowers the price target from $36 to $34. ALKS
Read More 18 minute read Earnings Markets News Pre-Market Outlook Earnings Scheduled For July 27, 2022 By Benzinga Insights July 27, 4:43 AM Companies Reporting Before The Bell • Equinor (NYSE:EQNR) is projected to report earnings for its second quarter. ACGL
Read More 1 minute read Earnings Earnings Preview: Alkermes By Benzinga Insights July 26, 10:29 AM Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-07-27. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will report an earnings per share (EPS) of $0.01. ALKS
Read More 3 minute read Analyst Color Analyst Ratings Biotech General Incyte (INCY) Outperforms Industry YTD: What Lies Ahead? By Zacks July 12, 1:33 PM Image sourced from Shutterstock AA